Search Within

Matthew J Matasar

  1. "Molecular Imaging and Therapy Service"
Formats
  1. Meeting Abstract (27)
  2. Journal Article (19)
  3. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (47)
  2. Department of Medicine (47)
  3. Hematologic Malignancies, Division of (47)
  4. Lymphoma (47)
  5. Molecular Imaging and Therapy Service (47)
  6. Radiology, Department of (47)

More Groups

People
  1. Andrew Zelenetz (45)
  2. Heiko Schoder (43)
  3. David Straus (40)
  4. Paul Hamlin (40)
  5. Anita Kumar (39)
  6. Alison Moskowitz (38)

More People

Years
  1. 2024 (2)
  2. 2023 (3)
  3. 2022 (4)
  4. 2021 (8)
  5. 2020 (3)
  6. 2019 (5)

More Years

Publications
  1. Blood (22)
  2. Hematological Oncology (5)
  3. Journal of Clinical Oncology (5)
  4. Haematologica (3)
  5. American Journal of Hematology (1)
  6. Annals of Oncology (1)

More Publications

Publishers
  1. American Society of Hematology (23)
  2. Wiley Blackwell (6)
  3. American Society of Clinical Oncology (5)
  4. Ferrata Storti Foundation (3)
  5. American Association for Cancer Research (1)
  6. Elsevier Inc. (1)

More Publishers

Results (47)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Imaging for staging and response assessment in lymphoma
    Journal Article

    Johnson, S. A.; Kumar, A.; Matasar, M. J.; Schòˆder, H.; Rademaker, J.
    Radiology (2015)

    Fulltext@MSK | Save
  • Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma
    Journal Article

    Sauter, C. S.; Matasar, M. J.; Meikle, J.; Schoder, H.; Ulaner, G. A.; Migliacci, J. C.; Hilden, P.; Devlin, S. M.; Zelenetz, A. D.; Moskowitz, C. H.
    Blood (2015)

    Fulltext@MSK | Save
  • PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: A non-randomised, open-label, single-centre, phase 2 study
    Journal Article

    Moskowitz, A. J.; Schòˆder, H.; Yahalom, J.; Mccall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Lancet Oncology (2015)

    Fulltext@MSK | Save
  • Safety and early efficacy in an ongoing pilot study of brentuximab vedotin and AVD chemotherapy followed by 30 gray involved-site radiotherapy for newly diagnosed, early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Yahalom, J.; Schoder, H.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; Hamilton, A.; Hamlin, P.; Horwitz, S. M.; Jacob, A. G.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A.; Schoder, H.; Gerecitano, J. F.; Hamlin, P.; Horwitz, S. M.; Matasar, M. J.; Keskinyan, V. S.; McCall, S.; Noy, A.; Palomba, M. L.; more...
    Blood (2013)

    Fulltext@MSK | Save
  • Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma
    Journal Article

    Moskowitz, C. H.; Matasar, M. J.; Zelenetz, A. D.; Nimer, S. D.; Gerecitano, J.; Hamlin, P.; Horwitz, S.; Moskowitz, A. J.; Noy, A.; Palomba, L.; more...
    Blood (2012)

    Fulltext@MSK | Save
  • Risk-adapted therapy using biopsy confirmation of abnormal interim FDG-PET for patients with advanced stage diffuse large B cell lymphoma (DLBCL), and exploratory evaluation of FLT-PET
    Meeting Abstract

    Moskowitz, C. H.; Schoder, H.; Hamlin, P. A.; Gerecitano, J. F.; Horwitz, S. M.; Matasar, M. J.; Moskowitz, A. J.; Noy, A.; Palomba, M.; Portlock, C. S.; more...
    Annals of Oncology (2011)

    Fulltext@MSK | Save